Conclusions. NT-proBNP have a significant predictive value for survival of CAPD patients and may be of value in guiding risk stratification and potentially targeted therapeutic interventions.
P lasma levels of cardiac natriuretic peptides are elevated in patients with chronic kidney disease, owing to impairment of renal function, hypertension, hypervolemia, and/or concomitant heart disease (1-7). Atrial natriuretic peptide (ANP) and particularly brain natriuretic peptide (BNP) levels are linked independently to left ventricular mass (3-5,8 -16) and function (3,6 -17) and predict total and cardiovascular mortality (1, 3, 8, 10, 12, 18) as well as cardiac events (12, 19) . ANP and BNP decrease significantly during hemodialysis treatment but increase again during the interdialytic interval (1,2,4,6,7,14,17,20 -23) . Levels in patients on peritoneal dialysis (PD) have been found to be lower than in patients on hemodialysis (11,24 -26) , but the correlations with left ventricular function and structure are maintained in both types of dialysis modalities (11, 15, 27, 28) .
The high mortality of patients on peritoneal dialysis and the failure of dialytic interventions to alter this mortality (29,30) necessitate renewed attention into novel methods of stratification and identification of patients at highest risk to be targeted for specific interventions. Cardiac natriuretic peptides are increasingly considered to fulfill this role in nonrenal patients. Evaluations of cardiac natriuretic peptides in patients on PD have been limited by small numbers (3,9,11,12,15,24 -26) and only one study examined correlations between natriuretic peptide levels and outcomes (12) . The PD population enrolled in the ADEMEX trial offered us the opportunity to evaluate cardiac natriuretic peptides and their value in predicting outcomes in the largest clinical trial ever performed on PD (29,30). It is hoped that such an evaluation would identify patients at risk even in the absence of overt clinical disease and hence facilitate or encourage interventions with salutary outcomes.
Concise Methods
We conducted a prospective randomized controlled clinical trial called ADEMEX, which examined the effect of increasing PD small solute clearances on select patient outcomes in individuals with ESRD treated with CAPD (29,30). The local clinical research committees of all participating centers approved the study protocol, and all study subjects gave written informed consent. Patients were recruited from 24 dialysis centers in 14 Mexican cities. The study enrolled 965 patients on CAPD between June 1998 and May 1999. Patients were randomized into either a control group (n ϭ 484 patients receiving a standard dose of 4 ϫ 2L CAPD) or an intervention group (n ϭ 481 patients receiving a modified CAPD prescription aimed at achieving a creatinine clearance Ն60L/wk/1.73 m 2 ). By design, the study was terminated in May 2001 when the last enrolled patient completed 2 yr of follow-up. A complete description of the study design, patient characteristics, etc. can be found in our previous publications (29,30). Although the ADE-MEX trial was not specifically designed to evaluate the prognostic significance of cardiac natriuretic peptides, the availability of neverthawed frozen plasma samples offered us the opportunity to undertake such an evaluation. Similar approaches have been successfully implemented in other large clinical trials (31). Determinations of cardiac natriuretic peptide concentrations were performed on baseline samples obtained from patients subsequently randomized to the control and intervention groups. We elected to measure the levels of inactive longer NH 2 -terminal fragments (i.e. NTproANP and NT-proBNP) rather than the biologically active shorter COOH-terminal peptides (i.e. ANP or BNP) because of the longer half-lives and consequently higher plasma concentrations of NT peptides. It has been suggested that these inactive peptides better fit the definition of a disease marker than do circulating concentrations of ANP or BNP (32) . Furthermore, because multiple assays for proANP exist with variable sensitivities that may affect clinical relevance (32), we simultaneously examined the concentrations of the full 98 amino acid NT peptide proANP(1-98) as well as smaller fragments [proANP and proANP(31-67)] (32). There is no universal consensus on which assays of proANP are best for risk stratification, hence our decision to examine multiple peptides.
Plasma concentrations of proANP(1-30), proANP(31-67), and proANP(1-98) were determined by competitive enzyme immunoassays (Biomedica, Vienna, Austria). The N-terminal fragment of NT-proBNP was determined by immunoassay (ECLIA, Roche, Mannheim, Germany). Plasma albumin was measured by the bromocresol purple method. Plasma concentration of interleukin-6 (IL-6) was measured by an immunoassay (R&D Systems, Wiesbaden, Germany) and N-high sensitive C-reactive protein (hsCRP) was determined by an immunonephelometric assay (Dade-Behring, Vienna, Austria).
Pearson 
Results

Patient Characteristics and Baseline Findings
The original design of the trial of two separate groups (control and intervention) was respected in the analysis examining the effects of natriuretic peptides. Patients in the two groups were similar at baseline with respect to various demographic measurements, comorbidities, dialysis parameters at baseline, select serum chemistries, inflammatory markers, and cardiac natriuretic peptides (Tables 1 and 2 ). By study design, patients in the intervention group had significantly greater peritoneal clearances compared with those in the control group. Specifically, over the course of the study, mean peritoneal creatinine clearances (mean Ϯ 1 SEM) averaged 46 Ϯ 0.45 L/wk/1.73 m 2 for the control group and 57 Ϯ 0.48 L/wk/1.73 m 2 for the intervention group (P Ͻ 0.001). Likewise, the mean peritoneal Kt/V values averaged 1.62 Ϯ 0.02 for control patients and 2.13 Ϯ 0.02 for intervention patients (P Ͻ 0.001). There was no significant difference in the time averaged GFR between the two groups (intervention-control mean difference of Ϫ0.20 Ϯ 0.11 ml/min, P ϭ NS), nor were there differences in normalized protein nitrogen appearance (nPNA), and serum albumin values over the course of the study.
Correlates of Baseline Natriuretic Peptides
Anephric patients (defined by a GFR Ͻ1 ml/min) had significantly higher plasma levels of NT-proBNP, proANP(1-30), and proANP(31-67) as compared with the nonanephric patients (defined by a GFR Ͼ1 ml/min) ( Table 3 ). ProANP(1-98) did not differ between the anephric group and the nonanephric group. When patients were subdivided into those with diabetes and those without diabetes, no difference was observed between Values are mean Ϯ SD. Incident: prevalent refers to the vintage of patients on dialysis. Incident patients by definition had been on dialysis for less than 3 mo when enrolled in the study and prevalent patients for more than 3 mo. diabetic and nondiabetic patients for any of the natriuretic peptides irrespective of the level of renal function. The pattern described for the effects of anephric status on natriuretic peptides, however, continued to be observed independent of diabetic status: diabetic and nondiabetic anephric patients had significantly higher plasma levels of NT-proBNP, proANP(1-30), and proANP(31-67) as compared with diabetic and nondiabetic nonanephric patients. Again, proANP(1-98) did not differ between anephric and nonanephric patients (Table 3) .
Baseline levels of natriuretic peptides correlated with a variety of parameters and among themselves (Table 4) . NT-proBNP was found to correlate with the other natriuretic peptides, mainly with pro-ANP(1-30) ( Table 4 ). There was a direct correlation between NT-proBNP and systolic BP and an inverse correlation between NT-proBNP and both urine volume and GFR. The correlation between NT-proBNP and GFR was significantly reduced (to r ϭ Ϫ0.09) when controlled for urine volume. The other natriuretic peptides also correlated with systolic BP, urine volume and GFR, but these correlations were greatly reduced when corrected for NT-proBNP. None of the natriuretic peptides was correlated with age, gender, or any anthropomorphic measures.
NT-proBNP correlated with inflammatory markers (inversely with albumin and directly with IL-6 and hsCRP). The correlation between NT-proBNP and albumin was reduced after correction for IL-6 but remained significant (r ϭ Ϫ0.175, Values are mean Ϯ SD. There was no difference between diabetic or nondiabetic patients for any of the peptides in either the anephric or the nonanephric groups. P Ͻ 0.001). The correlation between NT-proBNP and hsCRP lost its significance after controlling for IL-6. Controlling for urine volume did not eliminate the significant correlations between NT-proBNP and albumin (r ϭ Ϫ0.2524, P Ͻ 0.001) or NT-proBNP and IL-6 (r ϭ 0.2552, P Ͻ 0.001).
Predictive Value of Baseline Natriuretic Peptides
The value of baseline natriuretic peptides in predicting outcomes was explored by defining the population on the basis of median values of the respective natriuretic peptides (above or below the median value for the parameter of interest). NTproBNP had a significant effect on overall survival (all cause mortality; P Ͻ 0.001) that was independent of whether patients were on the control prescription (control) or the enhanced treatment (treatment) (Figure 1 ). The same was true of the effects of NT-proBNP on cardiovascular mortality independent of the treatment assignment (P Ͻ 0.001) (Figure 2 ). Cardiovascular mortality was defined as death due to any cardiac or cerebrovascular disease or event. In contrast, proANP(1-98) had no effect on overall survival (all cause mortality) in either treatment assignment group (Figure 3) . ProANP(1-98) also had no effect on cardiovascular survival in either treatment assignment group (data not shown). Similarly, neither proANP(1-30) nor proANP(31-67) had any effect on patient overall survival or patient cardiovascular mortality (data not shown).
To explore whether the observed effect of NT-proBNP on overall and cardiovascular survival was due to its association with another parameter, we performed a Cox stepwise regression for overall mortality risk (Table 5 ) including a variety of other parameters that influence survival in the model. In this analysis, we subdivided the values of IL-6, hsCRP, and NTproBNP into quintiles to further refine the stratification of patients at risk. In this model, hsCRP was not associated with survival. The lower quintile of IL-6 exhibited better survival. Each of the lower two quintiles of NT-proBNP was significantly associated with overall survival with the other quintiles as the Figure 1 . Patient overall survival (all cause mortality) by Nterminal pro-brain natriuretic peptide (NT-proBNP) and treatment assignment. The control (control) and the intervention (Treatment) groups were divided based on the median value of NT-proBNP. NT-proBNP had a significant effect on survival (P Ͻ 0.001) that was independent of the treatment assignment.
collective controls. The survival benefit was similar when the two lower quintiles were combined by the choice of a single cutoff value for the analysis (Ͻ3465 pg/ml).
In the aforementioned analysis, we included time-dependent measures for peritoneal ultrafiltration and urine volume because of the expected relevance of volume homeostasis components to natriuretic peptides. Because the issue of volume control is increasingly relevant in defining treatment guidelines in PD, we have further explored the effect of baseline fluid removal on prediction of outcomes. Groups were divided based on a value of fluid removal identified in the European Automated Peritoneal Dialysis Study (EAPOS) as correlated with survival (35) . Lower values of total fluid removal were significantly associated with an increase in all cause mortality (P Ͻ 0.01) independent of the treatment assignment (Figure 4) . Likewise, lower values of total fluid removal were significantly associated with increased cardiovascular mortality (P Ͻ 0.05) independent of the treatment assignment. Because fluid removal may vary over time, we explored the effect of this parameter on survival in a time-dependent analysis. Adjusted relative risks associated with time-dependent values of peritoneal ultrafiltration divided by quintiles were calculated. Relative risk calculations were adjusted for treatment group, gender, age, diabetes, cardiovascular disease, peripheral vascular disease, hypertension, prior time on dialysis, baseline values of GFR, total body water, albumin, nPNA, and time-dependent values of urinary volume. Patients in the lowest quintile had significantly higher relative risk of death.
Discussion
The findings of this study can be summarized as follows: plasma levels of cardiac natriuretic peptides are elevated in patients on PD; the levels observed correlate with the level of residual renal function and systolic BP; NT-proBNP [but neither proANP(1-30) nor proANP(31-67) or proANP(1-98)] is a powerful predictor of total as well as cardiovascular mortality.
Levels of cardiac natriuretic peptides have been known to reflect the severity of chronic kidney disease and to rise with diminishing GFR (36, 37) . Levels have been found to be elevated in patients on dialysis and to respond to manipulations in extracellular volume status (1,2,4,6,7,14,17,20 -23). In the study presented here, we observed high levels of cardiac natriuretic peptides in patients on PD. These levels were higher in anephric patients than in patients with some degree of residual renal function. In concordance with other studies (38 -40), we found no difference in natriuretic peptides levels between diabetic and nondiabetic patients. Others, however, had identified diabetes and obesity as associated with low plasma natriuretic peptide levels in the general population, and determined the negative effects of obesity and diabetes on natriuretic peptide levels to be additive (41) . In patients on PD in this study, neither diabetes nor anthropomorphic parameters had any effects on natriuretic peptides levels.
ANP and particularly BNP levels are linked independently to left ventricular mass (3-5,8 -16) and function (3,6 -17) and predict total and cardiovascular mortality (1, 3, 8, 10, 12, 18, 40) . This The values for peritoneal ultrafiltration represent the lowest quintile of the time-dependent analysis. Time-dependent analysis was also used for urine volume. The value for IL-6 represents the lowest quintile of the baseline value. For NTproBNP, the two lowest quintiles are those identified in the table. (1-98). ProANP(1-98) had no effect on survival in either treatment assignment groups. study, however, demonstrates that only NT-proBNP and not proANP(1-30), proANP(31-67), or proANP(1-98) is of predictive value in estimating all-cause and cardiovascular mortality in PD patients. ANP and BNP are synthesized and secreted mainly by cardiomyocytes. It is believed that ANP is preferentially produced in the atria, whereas BNP is preferentially synthesized in the ventricles, particularly in patients with chronic cardiac diseases (42) . Chronic cardiac dysfunction induces the secretion of a greater amount of BNP than ANP (42) . This may explain why in our study as well as in others [reviewed in (42) ] NT-proBNP is a better diagnostic/prognostic index compared with proANP. Furthermore, previous studies had utilized only one representative assay for proANP peptides. Because differing assays may have different sensitivities, which may affect clinical relevance, we thought it important to simultaneously evaluate multiple assays. Our results suggest that the poor predictive value of proANP peptides is not because of a selection of a low sensitivity assay.
NT-proBNP is an inactive cleavage product with much slower clearance than the biologically active BNP (43, 44) . Its plasma concentration, therefore, principally reflects myocardial secretion over a prolonged time. Prior investigations have identified plasma BNP and NT-proBNP levels as independent predictors of mortality or cardiovascular events in populations with chronic heart failure (45, 46) , acute coronary syndromes (47, 48) , prior myocardial infarction (49,50), established vascular disease or elevated coronary risk (51, 52) , stable coronary heart disease (53), and in community-based samples (54, 55) . Evaluations in patients on PD have been limited by small numbers (3,9,11,12,15,24 -26) and only one examined correlation between natriuretic peptide levels and outcomes (12) .
Wang et al. showed that NT-proBNP is an important risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic PD patients and adds important prognostic information beyond that contributed by left ventricular hypertrophy, systolic dysfunction, and other conventional risk factors (12) . In the study presented here, we found that NT-proBNP was an independent predictor of allcause mortality as well as cardiovascular mortality. The predictive value of NT-proBNP persisted even after correction for other factors known to influence outcomes in patients on PD including age, diabetes, presence of peripheral vascular disease, baseline albumin and nPNA, urine volume, peritoneal ultrafiltration, and measures of chronic inflammatory status (IL-6, hsCRP) ( Table 5) . Concordant with other studies (56), we found that urine volume was an independent predictor of outcome, and although levels of NT-proBNP correlated with levels of residual renal function (Tables 3 and 4) , the effect of NT-proBNP on patient outcome persisted even after correction for the effect of urine volume (Table 5) .
We and others (35) have found a relationship between peritoneal ultrafiltration and patient outcome. In the EAPOS trial, baseline peritoneal ultrafiltration was predictive of outcome, but not time-dependent peritoneal ultrafiltration (35) . In the study presented here, we have reproduced the findings of EAPOS pertaining to baseline peritoneal ultrafiltration and have shown that when examined by quintiles, time-dependent peritoneal ultrafiltration is also predictive of outcomes (only for the lowest quintile used in Table 5 ). This analysis was performed because of the expected importance of controlling for factors affecting volume homeostasis when exploring the role of cardiac natriuretic peptides. Care should be taken, however, in the interpretation of these findings out of this particular context. The relevance of fluid removal volume in the absence of concomitant information about salt/fluid intake and volume status is questionable.
In a previous report (29), we had described the observation of a very small (100 ml/d) albeit statistically significant difference in time-averaged daily peritoneal ultrafiltration between the control and the intervention groups. The two groups, however, did not differ in terms of survival (29). It is difficult to assign clinical significance to this minimal difference. As pertains to natriuretic peptides, however, the study presented here demonstrated that the predictive value of baseline NT-proBNP was independent of treatment assignment.
Along with myocardial stretch, a variety of other factors have been found to stimulate or enhance secretion of BNP in vitro, including myocardial ischemia and paracrine or endocrine agents (57) . This may explain why the predictive value of plasma NT-proBNP concentration was not eliminated by correction for other indices of volume balance. It may also imply that levels of NT-proBNP may be dependent on local and circulating factors that drive inflammation, fibrosis, and hypertrophy throughout the cardiovascular system (57) . Indeed, we did find significant correlations between levels of NT-proBNP and inflammatory markers such as IL-6, hsCRP, and albumin. It is well known that cytokines (particularly TNF-␣, IL-1, and IL-6) have a direct stimulating effect on cardiac natriuretic peptide secretion independent of other stimuli (42) .
In the Cox regression model (Table 5) , the various biomarkers had significant independent predictive value for all-cause (35) . Total fluid removal (Vol) had a significant effect on survival (P Ͻ 0.01) that was independent of the treatment assignment. mortality (Table 5 ). The persistence of the effect of NT-proBNP in the presence of other factors such as overt clinical disease, fluid removal, and inflammatory mediators suggests that it is an important indicator relevant for risk stratification. It has been suggested that combined use of biomarkers may enhance their predictive value (58) . Scoring methods for such biomarker combinations, however, have not been systematized or validated and may be confounded by intermarker correlations.
In conclusion, our results suggest that cardiac natriuretic peptides such as NT-proBNP are independently predictive of all-cause mortality and cardiovascular mortality. Elevated levels of NT-proBNP may identify CAPD patients at risk for higher cardiovascular mortality. These observations invite serious consideration of these biomarkers as potential triggers for targeted therapeutic intervention. We recognize that correlation of a biomarker with an outcome is insufficient on its own to trigger a therapeutic intervention or even define the nature of the intervention. However, several lines of evidence suggest the need for evaluative studies. First, cardiovascular mortality remains exceedingly high in ESRD, and NT-proBNP is linked prognostically as well as diagnostically to cardiovascular disease burden. Second, levels of NT-proBNP are responsive to therapeutic interventions. Third, NT-proBNP guided treatment of patients with congestive heart failure has resulted in improved outcomes (59) . 
